LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

Rhea-AI Summary

LIR Life Sciences (OTC:BBCMF) has begun Project Phase 2 peptide design with Neuland Laboratories to optimize next-generation cell-penetrating peptides for its transdermal delivery platform. Phase 2 focuses on structure-activity relationship (SAR) analysis of protamine-based sequences to identify third‑generation candidates with improved transport, synthetic efficiency and formulation flexibility.

Neuland and LIR will refine peptide structures and prioritize synthesis targets to inform later synthesis, formulation and biological testing stages.

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce that it has commenced Project Phase 2 peptide design activities with Neuland Laboratories Limited ("Neuland") under the parties' existing services agreement (please see news release dated January 8, 2026).

Project Phase 2 of the collaboration focuses on the design and optimization of next-generation cell-penetrating peptides intended to support LIR's transdermal delivery platform. Extending from a successful completion of Project Phase 1 synthesis work, the current program involves systematic structure-activity relationship (SAR) analysis to guide the development of third-generation peptide candidates with improved performance and potential for manufacturability.

The Project Phase 2 program is designed to explore a series of synthetic variants derived from LIR's lead protamine-based sequences. The objective is to identify optimized candidates that maintain strong transdermal transport activity while improving synthetic efficiency and formulation flexibility.

Neuland and LIR are working collaboratively to refine representative peptide structures and establish prioritized synthesis targets for subsequent evaluation. Results from this design project phase are expected to inform future synthesis, formulation, and biological testing programs.

"Advancing into Project Phase 2 design work with Neuland marks a meaningful step forward in the execution of our peptide development strategy," said Edward Mills, CEO of LIR Life Sciences. "Project Phase 1 activities are ongoing and continue to validate the practical feasibility of the underlying chemistry, while enabling the generation of foundational building blocks for continued evaluation. This next project phase is centered on deepening our understanding of structure-activity relationships, which play a critical role in guiding rational optimization and candidate selection. Work in this project phase is designed to inform decisions related to molecular design, quality attributes, and future manufacturability considerations, helping position the program for progression into subsequent stages of development."

About LIR Life Sciences Corp.
LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The Company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.

ON BEHALF OF LIR LIFE SCIENCES CORP.,

"Dr. Edward Mills,"
Chief Executive Officer

For more information, please contact:

Dr. Edward Mills
Chief Executive Officer
Tel: +1 888 436 7772
Email: investors@lirlife.com

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Cautionary Note Regarding Forward-Looking Information
This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as "believe", "project", "aim", "expect", "anticipate", "estimate", "intend", "strategy", "future", "opportunity", "plan", "may", "should", "will", "would", and similar expressions and, in this news release, includes statements relating to the research and development activities of the Company, the financial and business prospects of the Company, its assets and other matters. In particular, forward-looking information includes statements regarding the Company's transdermal delivery platform, the potential compatibility of the platform with GLP/GIP-based medicines, the anticipated outcomes of preclinical studies, and the potential development of future needle-free metabolic therapies. Although the Company believes that the expectations and assumptions on which such forward- looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.

SOURCE: Lir Life Sciences Corp.

View the original press release on ACCESS Newswire

FAQ

What is LIR Life Sciences (BBCMF) Project Phase 2 with Neuland?

Phase 2 is a peptide design program to optimize next‑generation cell‑penetrating peptides. According to the company, it focuses on SAR analysis of protamine‑based sequences to improve transdermal transport, synthetic efficiency and formulation flexibility before selecting candidates for synthesis and testing.

How does Phase 2 (BBCMF) differ from Project Phase 1 work?

Phase 2 emphasizes design and SAR analysis rather than initial synthesis activities. According to the company, Phase 1 produced foundational synthesis work and building blocks while Phase 2 aims to refine structures and prioritize candidates for further evaluation.

What outcomes should investors expect from BBCMF's Phase 2 peptide design?

Investors should expect optimized peptide candidates and prioritized synthesis targets for follow‑on testing. According to the company, results will inform future synthesis, formulation and biological testing programs and guide manufacturability considerations.

What is the strategic importance of Neuland's role in BBCMF's Phase 2 program?

Neuland provides collaborative design and synthesis expertise to accelerate peptide optimization. According to the company, the partnership refines representative structures and sets prioritized synthesis targets to support candidate selection and downstream development.